Stem Cell Clinic

NANT Pediatric Cancer Consortium Spearheads Research That Identifies Targeted Therapy for High-Risk Neuroblastoma – Newswise

Newswise It is rare that a clinical trial is changed mid-investigation. But when results are striking enough, it can occur. Such striking results have been reported in a study led by the New Approaches to Neuroblastoma (NANT) pediatric cancer consortium, which is headquartered at Childrens Hospital Los Angeles.

For patients with relapsed or refractory neuroblastoma who have an alteration in the ALK gene, lorlatinib has been shown to be a safe, effective targeted therapy. This phase 1 findingpublished today in Nature Medicineis so significant that the Childrens Oncology Group (COG) is now modifying its phase 3 protocol to replace another ALK inhibitor (crizotinib) with lorlatinib to treat newly diagnosed neuroblastoma arising from an ALK alteration.

NANT is the only clinical trials consortium focused on developing new treatments and biomarkers for children and young adults with neuroblastoma. It is an international collaboration of expert investigators from around the world working to fast-track investigation into promising new therapies to benefit young patients with neuroblastoma.

Araz Marachelian, MD, Medical Director of NANTs Operations Center and Medical Director of CHLAs Neuroblastoma MIBG Program, is the studys sponsor and co-senior author on the Nature Medicine publication.

At NANT, we are pleased to have had a leadership role in this important discovery, says Dr. Marachelian. NANTs participation included early collaboration on evaluating laboratory data, trial design, securing FDA approval and industry sponsorship, study oversight and coordination, safety monitoring, creating and maintaining the study database, and analyzing and disseminating study results.

Neuroblastoma is the third most common cancer in children and originates in the nerve cells outside the brain of infants and young children. It most commonly affects children 5 years of age or younger. Half of patients are considered to have high-risk disease and require intensive therapy that includes chemotherapy and biologic therapy, surgery, transplant, radiation and immunotherapy. Despite this multimodal approach, only 50% of high-risk patients survive.

We are thrilled to see many years of NANTs planning and operation come to fruition with the results of this important study, says Julie Park, MD, Chair of the NANT consortium. Families are urgently waiting for new treatment possibilities like this one. Dr. Park is an established neuroblastoma expert and chair of the Department of Oncology at St. Jude Childrens Research Hospital.

NANT brings together a diverse team of investigators that cannot be found at a single institution to identify promising treatment candidates, perform preclinical testing and then to design and carry out early-phase testing of these novel treatments. Because neuroblastoma is a rare disease with only 700 to 800 new cases in the U.S. each year, no single site could enroll enough patients to produce meaningful data. NANT sites enroll patients and collect consistent data that can then form the basis for a Childrens Oncology Group clinical trial and offer patients access to novel therapies across a broad geographic area in North America and Europe.

First author on the paper is Kelly C. Goldsmith of Childrens Healthcare of Atlanta and co-senior author is Yael P. Mosse of Childrens Hospital of Philadelphia. The trial was conducted at national and international sites including: Vanderbilt University Medical Center, Childrens Hospital Los Angeles, USC Keck School of Medicine, Childrens Hospital of Philadelphia, University of Iowa Hospital and Clinics, Childrens Hospital of Philadelphia, Stanford University School of Medicine, Perelman School of Medicine at the University of Pennsylvania, The Royal Marsden Hospital, London, UK, Cook Childrens Medical Center, , Department of Pediatrics, University of Chicago, Department of Pediatrics, University of Michigan, Hospital for Sick Kids, Toronto, ON, Harvard Medical School, Childrens Hospital Colorado, Seattle Childrens Hospital, Institut Curie, Paris, France and UCSF Benioff Childrens Hospital.

The study was funded by National Cancer Institute grant P01CA217959, Pfizer Inc. and other grants and foundations.

About Childrens Hospital Los Angeles Childrens Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country, and the greater Southern California region. Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No. 1 pediatric hospital in the Pacific region and California, and among the top 10 in the nation on U.S. News & World Reports Honor Roll of Best Childrens Hospitals. Clinical expertise spans the pediatric care continuum for newborns to young adults, from everyday preventive medicine to the most advanced cases. Inclusive, kid- and family-friendly clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC, and proven discoveries reach patients faster through The Saban Research Institute of Childrens Hospital Los Angelesamong the top 10 childrens hospitals for National Institutes of Health funding. The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the western United States. To learn more, follow us on Facebook, Instagram, LinkedIn, YouTube and Twitter, and visit our blog at CHLA.org/blog.

See the article here:
NANT Pediatric Cancer Consortium Spearheads Research That Identifies Targeted Therapy for High-Risk Neuroblastoma - Newswise

Rare Neurological Disease Treatment Market is estimated to be US$ 18367 million by 2030 with a CAGR of 7.50% – – EIN News

Rare Neurological Disease Treatment Market -PMI

The report "Rare Neurological Disease Treatment Market, By Drug Type and By Region - Market Trends, Analysis, and Forecast till 2030

The report "Rare Neurological Disease Treatment Market, By Drug Type (Biologics and Small Molecules), By Mode of Administration (Injectables, Oral and Other Modes of Administration), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Key Highlights: In 2021, -Global Genes, a prominent international rare illness advocacy organisation, today announced the beginning of a multi-stakeholder programme called Patient Identification and Engagement for RARE CNS Disorders (PIE4CNS). The PIE4CNS initiative will address major gaps in the timely and comprehensive diagnosis of rare central nervous system (CNS)-related conditions, as well as challenges in finding and engaging patient populations in clinical research in gene therapy and other promising technologies that could lead to significant advancements in rare disease treatment.

Analyst View: The absence of appropriate therapy is the most notable driving factor for the market's main players, which will assist it develop in the forecast period's approaching years. A focus on fast-track approvals for novel and future medicines to treat such illnesses is another major element for market growth. Furthermore, recent technical breakthroughs in the fields of neurology and neurobiology have aided the growth of the global market for neurological disorder therapy. In addition, raising awareness about early detection of these conditions may aid market growth in the coming years.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4840

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Outlook for Rare Neurological Disease Treatment Strategies Key Questions this Study will Answer Market Snippet, By Drug Type Market Snippet, By Mode of Administration >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Rare Neurological Disease Treatment Market, By Drug Type, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Biologics Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Small Molecule Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 4.Global Rare Neurological Disease Treatment Market, By Mode of Administration, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Injectables Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Orals Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: Global Rare Neurological Disease Treatment Market accounted for US$ 8931.49 million in 2020 and is estimated to be US$ 18367 million by 2030 and is anticipated to register a CAGR of 7.50%. The Global Rare Neurological Disease Treatment Market is segmented based on drug type, mode of administration and region. Based on Drug Type, Global Rare Neurological Disease Treatment Market is segmented into Biologics and Small Molecules. Based on Mode of Administration, Global Rare Neurological Disease Treatment Market is segmented into Injectables, Oral and Other Modes of Administration. By Region, the Global Rare Neurological Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Rare Neurological Disease Treatment Market: CSL Ltd Kedrion Biopharma Inc US WorldMeds LLC Merz Pharma GmbH & Co. KGaA Aquestive Therapeutics Inc Bayer AG Pfizer Inc Novartis AG Merck & Co. Inc. (EMD Serono Inc.) Jazz Pharmaceuticals PLC.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period

Questions answered by Rare Neurological Disease Treatment Market:

1.What is the current size of the rare neurological disease treatment market, and what are the growth projections for the market in the coming years? The current size of the rare neurological disease treatment market is estimated to be around $10 billion. The market is projected to grow at a compound annual growth rate (CAGR) of around 6% during the forecast period from 2021 to 2028, driven by factors such as increasing prevalence of rare neurological diseases, growing investments in R&D, and favorable government initiatives.

2.What are the major drivers and challenges in the rare neurological disease treatment market, and how are they impacting the growth of the market? The major drivers in the rare neurological disease treatment market include increasing prevalence of rare neurological diseases, growing investments in R&D, and favorable government initiatives. However, the market also faces challenges such as high cost of treatments, limited patient population, and difficulty in diagnosis and clinical trials. These factors can impact the growth of the market by influencing access to treatments, funding for research, and regulatory policies.

3.What are the major trends in the rare neurological disease treatment market, and how are they expected to shape the market in the future? Some of the major trends in the rare neurological disease treatment market include increasing adoption of precision medicine, growing focus on gene therapy and biologics, and development of innovative treatment approaches such as gene editing and stem cell therapy. These trends are expected to shape the market by improving treatment outcomes and expanding the range of treatment options available for rare neurological diseases. Additionally, the emergence of digital technologies such as telemedicine and wearable devices is also expected to revolutionize the way rare neurological diseases are diagnosed and treated.

Browse Other Related Research Reports from Prophecy Market Insights: Smart Pills Market: By Target Area (Small Intestine, Large intestine, Stomach, and Esophagus), By Application (Drug Delivery, Capsule Endoscopy and Others), By End-Users (Hospitals, Diagnostic Centers, Specialty Clinics and Research Institutes) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Elderly Care Market: By Product Type (Pharmaceuticals, Housing and Assistive Devices), By Service (Institutional Care, Homecare, Adult Day Care), By Application (Heart Diseases, Cancer, Kidney Diseases, Diabetes, Arthritis, Osteoporosis, Neurological, Respiratory and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+1 860-531-2574email us hereVisit us on social media:FacebookTwitterLinkedIn

Read the rest here:
Rare Neurological Disease Treatment Market is estimated to be US$ 18367 million by 2030 with a CAGR of 7.50% - - EIN News

Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast – EIN News

Pharmerging Market-By PMI

Pharmerging Market, By Products, By Economy , By Indication, By Distribution Channel and By Region - Trends, Analysis and Forecast till 2030

Region Analysis: The Middle East and Africa, Asia Pacific, North America, and Europe are all regions where the worldwide pharmerging market is reported to be present. In 2020, Asia Pacific dominated this market due its fast urbanization, rising patent expiration, and spike in spending in medical research, researchers. As the primary domestic market for pharmaceutical innovation in Asia Pacific, China has emerged. Europe and Latin America are projected to have strong growth in the near future, among other geographical markets for pharmerging. The Latin American healthcare industry is anticipated to grow due to technological improvements, significant research and development techniques, and rising public awareness of the administration and treatment of healthcare facilities

Key Highlights: In 2022, Saudi pharmaceutical company Jamjoom Pharma has announced the opening of a new factory in Egypt as it looks to expand its exports to newer markets in Africa. During the partnership signing event between Egypt and Saudi Arabia, the announcement was made. In 2022, Medical Marijuana, Inc., the world's first publicly traded cannabis company to introduce cannabis-derived nutraceutical products, brands, and supply chains, announced today that its first pharmaceutical subsidiary, HM Pharma, has begun operations in Brazil.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4894

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Pharmerging Market Key Questions this Study will Answer Market Snippet, By Product Type Market Snippet, By Economy Market Snippet, By Indication Market Snippet, By Distribution Channel Market Snippet, By Region >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Pharmerging Market, By Product, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Pharmaceuticals Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Healthcare Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 4.Global Pharmerging Market, By Economy , 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Tier-1 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Tier-2 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Tier-3 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 5.Global Pharmerging Market, By Indication, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Lifestyle Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Cancer & Autoimmune Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Infectious Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 6.Global Pharmerging Market, By Distribution Channel, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Hospitals Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Clinincs Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Retail Pharmacies Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >E-Commerce Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Drug Stores Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: Pharmerging Market size accounted for US$ 971.94 billion in 2020 and is estimated to be US$ 4426.72 billion by 2030 and is anticipated to register a CAGR of 16.5%. The Global Pharmerging Market is segmented based on product type, economy, indication, distribution channel and region. Based on Product Type, Pharmerging Market is segmented into Pharmaceuticals, Healthcare and Others (IT and Record Management). Based on Economy, Pharmerging Market is segmented into Tier-1, Tier-2 and Tier-3. Based on Indication, Pharmerging Market is segmented into Lifestyle Disease, Cancers & Autoimmune Diseases and Infectious Disease. Based on Distribution Channel, Pharmerging Market is segmented into Hospitals, Clinics, Retail Pharmacies, E-Commerce and Drug Stores. By Region, the Pharmerging Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Pharmerging Market: Sanofi S.A. Pfizer Inc. AstraZeneca Plc GlaxoSmithKline Plc F. Hoffmann-La Roche AG (Roche AG) Eli Lilly and Company Johnson & Johnson Abbott Laboratories Novartis AG Teva Pharmaceutical Limited

Questions answered by Pharmerging Market: What are the major drivers and challenges in the pharmerging market, and how are they impacting the growth of the market? The major drivers in the pharmerging market include growing demand for healthcare services, increasing government initiatives for healthcare infrastructure development, rising disposable incomes and middle-class population, and increasing prevalence of chronic diseases. However, the market also faces challenges such as limited healthcare access in remote and rural areas, inadequate healthcare funding, lack of skilled healthcare professionals, and strict regulatory policies. These factors can impact the growth of the market by influencing the development, manufacturing, and distribution of pharmaceutical products in pharmerging markets.

What are the different types of pharmaceutical products available in the pharmerging market, and what are their applications? The different types of pharmaceutical products available in the pharmerging market include branded and generic drugs, biologics, vaccines, and medical devices. These products are used to treat a wide range of diseases and conditions, including infectious diseases, cardiovascular diseases, cancer, diabetes, and respiratory diseases. Additionally, there is an increasing focus on developing innovative therapies such as gene therapy and cell therapy to address unmet medical needs in pharmerging markets. The pharmaceutical products in pharmerging markets are often priced lower than those in developed markets to make them more affordable for the local population.

What are the major distribution channels for pharmerging market products, and how are they evolving? The major distribution channels for pharmerging market products include retail pharmacies, hospitals and clinics, e-commerce platforms, and wholesalers/distributors. In recent years, there has been a shift towards online sales of pharmaceutical products in pharmerging markets, driven by increasing internet penetration and smartphone usage. E-commerce platforms are becoming popular as they provide convenient access to a wide range of pharmaceutical products at competitive prices. Additionally, the use of mobile health (mHealth) technologies for medication management and remote monitoring is also gaining traction in pharmerging markets. However, the traditional distribution channels such as retail pharmacies and hospitals/clinics still play a significant role in the distribution of pharmaceutical products in pharmerging markets, particularly in remote and rural areas with limited internet connectivity.

Browse Other Related Research Reports from Prophecy Market Insights: Prils Market: By Type (Amipril, Quinapril, Cilazapril, Benazepril and Others), By Application (Hypertension, Heart Failure, Chronic Kidney Disorders, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Thalassemia Treatment Market: By Type (Alpha-Thalassemia and Beta-Thalassemia), By Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy and Bone Marrow Transplant), By End-User (Hospitals & Clinics, Diagnostic Laboratories and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+ +1 860 531 2574email us hereVisit us on social media:FacebookTwitterLinkedIn

Visit link:
Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast - EIN News

Streamline Your Workflow and Boost Productivity with the Latest Medical Transcription Software – EIN News

Medical Transcription Software Market

Medical transcription software converts digital voice recordings into text that will be used and accessed by medical professionals.

The software can help alleviate the workloads of physicians and ultimately prevent burnout. Nurses, physicians, and doctors dictate or feed voice recordings into the medical transcription solution and the solution produces text and reports that can be stored within a patients digital files.

: https://www.alliedmarketresearch.com/request-sample/31904#UTM_Source=EIN-Mahendra

The global medical transcription software industry generated $1.6 billion in 2021, and is anticipated to generate $7.0 billion by 2031, witnessing a CAGR of 15.5% from 2022 to 2031.

Medical transcription software has a significant scope in hospitals and clinics applications as it can help healthcare professionals streamline their documentation processes, improve accuracy, and reduce administrative workload.

:

Improved accuracy: Medical transcription software uses advanced technologies such as natural language processing and voice recognition to ensure accurate and error-free transcription of medical records.

(254 , , , ) @ https://www.alliedmarketresearch.com/medical-transcription-software-market/purchase-options#UTM_Source=EIN-Mahendra

: The software automates the transcription process, allowing healthcare professionals to save time and focus on patient care. This can result in increased productivity and reduced administrative workload.

: Medical transcription software often comes with advanced security features such as encryption, access control, and backup and recovery options, which can ensure the security and confidentiality of patient records.

: Many medical transcription software solutions can seamlessly integrate with electronic health record (EHR) systems, making it easier for healthcare professionals to access and update patient records.

: By reducing administrative workload and increasing efficiency, medical transcription software can help hospitals and clinics save on operational costs.

- https://www.alliedmarketresearch.com/purchase-enquiry/31904#UTM_Source=EIN-Mahendra

2031

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for nearly two-fifths of the global medical transcription software market, and is likely to dominate the market during the forecast period. This is attributed to the surge in demand for better healthcare facilities, rise in the demand for medical transcription solution, and government reforms for the acceptance of medical transcription in the region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 17.2% from 2022 to 2031. This is owing to the increase in prevalence of chronic diseases, rise in awareness related to the use of medical transcription services, and surge in healthcare expenditure.

: - 3M, Dolbey System, Inc., Global Medical Transcription, DeepScribe, Inc., Microsoft Corporation (Nuance Communication, Inc.), Amazon, Inc. (Amazon Web Services, Inc.), ZyDoc Medical Transcription, SmartMD, AQuity Solutions, iMedX.

- https://www.alliedmarketresearch.com/stem-cell-and-gene-therapy-biological-testing-market-A13443

- https://www.alliedmarketresearch.com/heart-attack-diagnostics-market-A12689

- https://www.alliedmarketresearch.com/huntington%E2%80%99s-disease-treatment-market-A17522

David CorreaAllied Analytics LLP+1 800-792-5285email us here

Original post:
Streamline Your Workflow and Boost Productivity with the Latest Medical Transcription Software - EIN News

Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030 … – InvestorsObserver

Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030, Says Coherent Market Insights (CMI)

Burlingame, April 04, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global pediatric vaccines market is estimated to be valued at US$ 46,424.3 million in 202 3 and is expected to exhibit a CAGR of 5.9% during the forecast period (202 3 -2030 ).

Analysts Views on Global Pediatric Vaccines Market:

Government authorities in the India are focusing on conducting campaigns in order to provide vaccines to children, and this is expected to drive the growth of the market over the forecast period. For instance, on December 17, 2022, The Pune Municipal Corporation (PMC), India, held a special measles vaccination campaign in which 470 children in pune were immunized. Thus, increasing vaccination campaigns through government authorities can boost the market growth in near future.

Key Trends and Analysis of the Global Pediatric Vaccines Market :

Increasing vaccines approval for pediatric age group by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on October 19, 2022, European Medicines Agency (EMA) recommended approval of Comirnaty and Spikevax COVID-19 vaccines for children of 6 months of age. EMAs human medicines committee (CHMP) has recommended extending the usage of Comirnaty and Spikevax that targets original strain of SARS-CoV-2. The Committee recommended usage of Comirnaty in children aged 6 months to 4 years and usage of Spikevax in children aged 6 months to 5 years. Comirnaty and Spikevax are already approved by EMA for being used in both adults and children aged from 5 and 6 years, respectively.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1708

Global Pediatric Vaccines Market - Driver s

Increasing vaccine approvals by regulatory authorities

Increasing vaccine approvals by regulatory authorities is expected to drive the Global Pediatric Vaccines Market over the forecast period. For instance, on October 15, 2021, Seqirus, a global leader in influenza prevention, and a business of CSL Limited, a biotechnology company announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX QUADRIVALENT (Influenza Vaccine), Seqiruss cell-based quadrivalent influenza vaccine for an expanded age indication for children of age six months old. FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine, in the U.S., is now indicated for everyone that is eligible to receive an influenza vaccine in the U.S.

Market players are focused on product evaluation for pipeline product

Market players are engaged in evaluating and demonstrating safety, tolerability, and immunogenicity of vaccines, and this is expected to boost overall growth of the market. For instance, in May 2020, Sanofi, a pharmaceutical and healthcare company has initiated a Phase 2 clinical trial study of pneumococcal conjugate vaccine. Objective of this study is to evaluate immunogenicity and safety of a pneumococcal conjugate vaccine when it is administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.

Pediatric Vaccines Market Report Coverage

Global Pediatric Vaccines Market - Restrain t

Reoccurrence of adverse events after immunization

Although millions of children and adults are vaccinated in order to prevent the occurrence of infectious diseases, such as the Flu, measles, strep throat, COVID-19, and salmonella, several research studies have evaluated reoccurrence of some adverse events after influenza vaccination. Such adverse events are associated with the most common adverse reactions to live or attenuated influenza vaccine (LAIV) are runny nose or nasal congestion in all ages, fever >100F in children 2-6 years of age, and sore throat in adults. Reoccurrence of adverse events after immunization results in declining interest of people for booster dose of influenza vaccines. Therefore, such incidences can pose major challenges such as decreasing community acceptance for vaccines, and this is expected to negatively affect the pediatric vaccines market growth.

Global Pediatric Vaccines Market - Opportunity

I ncreasing government campaigns for immunization program in various region

The government authorities are focusing on the immunization programme in lower-income countries in order to provide healthcare services, and to control the prevalence rate of infectious diseases, and thus, this requires increased production of pediatric vaccines that is expected to create opportunities for market players in the development and production of pediatric vaccine. For instance, on October 28, 2022, the Global Alliance for Vaccines and Immunization (GAVI) announced that GAVI is working with governments, communities, in a concerted effort to rollout measles vaccines to vulnerable children across low income countries such as Angola, Liberia, and others. From 2022 through the first half of 2023, Gavi plans to support 22 lower-income countries to undertake measles follow-up campaigns, aiming to reach more than 85 million vaccinated children.

Global Pediatric Vaccines Market Cross Sectional Analysis:

In Vaccine Type, MMR Vaccine segment is dominant during forecast period in North America region due to increasing product approvals by regulatory authorities in the market, and this is expected to drive segment growth over the forecast period. For instance, on June 6, 2022, GSK PLC, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Priorix (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps, and rubella (MMR) in children of 12 months of age and older. Priorix will be available in the U.S. market.

Global Pediatric Vaccines Market Segmentation:

The Global Pediatric Vaccines Market report is segmented into Vaccine Type, Technology, Type, Distribution Channel and Region

Based on Vaccine Type , the market is segmented into Pneumococcal Vaccine, DTP Vaccine, Rotavirus Vaccine, MMR Vaccine, Polio Vaccine, Influenza Vaccine, Hepatitis B Vaccine, Meningococcal Vaccine, Hib Vaccine, and Varicella Vaccine. Out of which, pneumococcal vaccine segment is expected to dominate in global pediatric vaccines market during the forecast period, due to increasing inorganic growth strategies such as collaboration by key players in the market.

Based on Technology , the market is segmented into Live or Attenuated Vaccine, Inactivated or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine, Recombinant Vaccine. Out of which, Subunit Vaccine segment is expected to dominate in the market over the forecast period, due to increasing launches of Subunit Vaccine is expected to increase the growth of the segment over the forecast period. For instance, in 2020, Abbott, a healthcare company launched a new inactivated quadrivalent vaccine which is subunit vaccine for influenza in India.

Based on Type , the global pediatric vaccines market is segmented into Monovalent Vaccine and Multivalent Vaccine where Multivalent Vaccine segment is expected to dominate in the market over the forecast period due to prevalence of infectious disease.

Based on Distribution Channel , the global pediatric vaccines market is segmented into Government and Private. Of which, Government segment is expected to dominant in the market over the forecast period, due to increasing vaccination campaigns by government authorities.

Among all segmentation, Vaccine Type segment is expected to dominate in the market due to increasing adoption of inorganic growth strategies such as partnership by key market players in order to expand their product portfolio. For instance, in 2021, SEQIRUS., a global influenza vaccine company, announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvant), this influenza vaccine is helps in protecting individuals of six months of age and older against influenza A (H5N1) in the event of a pandemic.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1708

Global Pediatric Vaccines Market : Key Developments

In June 2022, GSK plc., a U.K.-based multinational pharmaceutical and biotechnology company, announced that the U.S. FDA has approved Priorix (Measles, Mumps, and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals of 12 months of age and older.

On June 18, 2022, the Centers for Disease Control and Prevention (CDC) has approved COVID-19 vaccination for young children of age 6 months old that means 20 million children, in the U.S., who are under 5 years are newly eligible for vaccination .

Key Market Takeaways:

Global Pediatric Vaccines Market is expected to exhibit a CAGR of 5.9% during the forecast period due to increasing effectiveness of vaccines developed by market players. For instance, in July 2021, Sanofi, a France-based multinational pharmaceutical and healthcare company, reported that its single-dose vaccine named MenQuadfi met all primary and secondary endpoints in Phase III MEQ00065 study in healthy toddlers for preventing invasive meningococcal disease (IMD), a fatal illness. The study compared the immune response against meningococcal serogroup C, and analyzed the safety of MenQuadfi in healthy toddlers aged 12 to 23 months against quadrivalent ACWY (four common types of meningococcal bacteria) vaccine, Nimenrix, and monovalent C vaccine, NeisVac-C.

Among Vaccine Type, pneumococcal vaccine segment is dominant due to increasing number of clinical trials for drug development, and this is expected to drive the segment growth over the forecast period. For instance, in April 2022, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

On the basis of Distribution Channel, government segment is expected to hold a dominant position over the forecast period, owing to increasing immunization campaigns in hospital by government authorities. For instance, on June 18, 2022, the Centers for Disease Control and Prevention (CDC) announced that all children of age 6 months to 5 years of age should receive a COVID-19 vaccine. This expands eligibility for vaccination to nearly 20 million additional children, and all Americans ages 6 months and older are now eligible for vaccination. Distribution of pediatric vaccinations for these younger children has started across the U.S. country, and will be available at thousands of pediatric practices, pharmacies, Federally Qualified Health Centers, local health departments, clinics.

Competitive Landscape:

Key players operating in the Global Pediatric Vaccines Market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.

Market Segmentation:

Related Market Intelligence Reports:

Plasmid DNA Manufacturing Market , By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 2030

Single-Use Bioreactor Market , By Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), By Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), By Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins, and Other Molecule Types), By End User (Pharmaceutical and Biopharmaceutical Industries and Contract Research Organizations (CRO) Other End Users), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedIn | Twitter

Read the rest here:
Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030 ... - InvestorsObserver

Uveal Melanoma Market is estimated to increase with a CAGR of 7.8% during the forecast period-By PMI – EIN News

Uveal Melanoma Market-By PMI

The report "Uveal Melanoma Market, By Diagnosis, By Therapy, By End-User, and By Region - Market Trends, Analysis, and Forecast till 2030

The report "Uveal Melanoma Market, By Diagnosis (Ultrasonography, Indocyanine green angiography, High resolution ultrasound Biomicroscopy and Others), By Therapy (Radiation therapy, Surgical resection techniques, Transpupillary thermotherapy and Others), By End-User (Hospital, Ambulatory surgical centers, Ophthalmology clinics and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Key Highlights: Immunocore Limited and Eli Lilly and Company announced on June 29, 2015 that they have formed an immunotherapy-based clinical trial partnership to test the efficacy of Immunocore's lead T cell receptor-based research therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib for the treatment of melanoma (LY2801653). In June 2018, Aura Biosciences, a biotechnology company focused on developing therapies that use viral capsid conjugates to target and selectively destroy cancer cells, released interim safety and efficacy data from an open-label Phase 1b/2 study of AU-011 for the treatment of primary choroidal melanoma.

Analyst View: The global market for uveal melanoma treatment is being driven by an increase in the number of cases of eye cancer. One of the key causes of the growth is assumed to be the rise in the use of technological devices. This could be linked to the harmful UV radiation emitted by cellphones, tablets, desktops, laptops, and other electronic devices. According to the American Cancer Society, adults aged 60 and up spend 5 or more hours each day on digital devices and prefer laptops and desktops for internet browsing. As a result, the uveal melanoma treatment market is expected to grow.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4726

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Outlook for Uveal Melanoma Strategies Key Questions this Study will Answer Market Snippet, By Diagnosis Market Snippet, By Therapy Market Snippet, By End-User Market Snippet, By Region >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Uveal Melanoma Market, By Diagnosis, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Ultrasonography Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Indocyanine green angiography Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >High resolution ultrasound Biomicroscopy Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

6.Global Uveal Melanoma Market, By Therapy, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Radiation therapy Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Surgical resection techniques Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Transpupillary thermotherapy Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 7.Global Uveal Melanoma Market, By End-User, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Hospitals Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Ambulatory surgical centers Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Ophthalmology Clinics Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: The Global Uveal Melanoma market is anticipated to register a CAGR of 7.8%. The Global Uvea Melanoma Market is segmented based on the diagnosis, therapy, end-user, and region. By Diagnosis, the Global Uveal Melanoma Market is segmented into Ultrasonography, Indocyanine green angiography, High resolution ultrasound Biomicroscopy and Others. By Therapy, the market is segmented in Radiation therapy, Surgical resection techniques, Transpupillary thermotherapy and Others. By End-User, the Global Uveal Melanoma Market is segmented into Hospital, Ambulatory surgical centers, Ophthalmology clinics and Others. By Region, the Global Uveal Melanoma Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the largest Uveal Melanoma Market share.

Competitive Landscape: Eli Lilly &Co Novartis AG Bayer AstraZeneca Amgen Pfizer Inc Roche Spectrum pharmaceuticals Many companies in the uveal melanoma treatment industry are attempting to expand their product offerings. However, the most effective way to increase the number of customers is to market the goods through internet portals. The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning. Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period.

Questions answered by Uveal Melanoma Market: What are the major factors driving the growth of the uveal melanoma market? The major factors driving the growth of the uveal melanoma market include increasing incidence of the disease, rising awareness and early detection, advancements in diagnostic techniques, and development of new therapies for the treatment of uveal melanoma. Additionally, the growing research on the disease biology and genetics is expected to lead to the development of more targeted and effective therapies for uveal melanoma in the future.

What are the implications of changes in healthcare policy and reimbursement for the uveal melanoma market? Changes in healthcare policy and reimbursement can have significant implications for the uveal melanoma market. These changes can impact the availability and affordability of treatments for patients, as well as the profitability of companies that develop and market these treatments. For example, changes in reimbursement policies may impact the pricing and access to therapies, and may also influence the development of new treatments. Additionally, changes in healthcare policy may impact the funding of research and development efforts related to uveal melanoma.

What are the key trends in the uveal melanoma market, such as new technologies and treatment approaches? The key trends in the uveal melanoma market include the development of new targeted therapies and immunotherapies, advancements in diagnostic techniques, and the increasing focus on personalized medicine approaches. Additionally, there is growing interest in the use of combination therapies and the development of biomarkers to help predict patient response to treatment. Emerging technologies such as gene therapy, RNA interference, and nanotechnology are also being explored as potential treatments for uveal melanoma.

Browse Other Related Research Reports from Prophecy Market Insights: Sandhoff Disease Treatment Market: By Type (Infantile, Juvenile and Late onset), By Treatment (Medication and Surgery), By Therapy (Gene therapy, Enzyme replacement therapy, Stem cell therapy and Others), By End-user (Hospital, Homecare, Specialty Clinics and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Rotavirus Prophylaxis Market: By Treatment (Rotavac, Rotarix, Rotavin-M1 and Others), By Route of Administration (Oral, Parenteral and Others), By End-user (Hospital, Homecare, Specialty centers and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+ +1 860 531 2574email us hereVisit us on social media:FacebookTwitterLinkedIn

See original here:
Uveal Melanoma Market is estimated to increase with a CAGR of 7.8% during the forecast period-By PMI - EIN News

Medical Tubing Market Research Report 2022 | Analysis, Trends, Business Growth and Forecast 2027 – EIN News

Medical Tubing Market Research Report

The global medical tubing market size reached US$ 11.72 Billion in 2021. By 2027, it will reach a value of US$ 18.18 Billion, growing at 7.30% (2022-2027).

Medical tubing refers to flexible, thin, plastic hoses that meet medical industry standards and requirements for a variety of surgical or pharmaceutical applications. It comprises tubes of various lengths and diameters integrated with catheters, peristaltic pumps, anesthesiology, respiratory equipment, intravenous (IV) therapy, and numerous biopharmaceutical laboratory equipment. It also consists of feeding tubes, which are essential for supplying nutrients to people who cannot get enough nutrition by eating or suffering from neurologic and neuromuscular disorders. Medical tubing is manufactured from polyethylene, polyvinyl chloride (PVC), and polypropylene plastic and is often softened with plasticizers to increase flexibility. It helps drain and collect urine from the bladder, monitor the urine output of patients, diagnose disorders in the lower urinary tract, and introduce various medications into the body. Medical tubing also assists in stenting or decompressing the small intestine to reduce pressure and address adhesion in affected areas and treat small bowel obstruction. It is utilized to drive catheters in cardiac catheterization and test for heart diseases and locate narrowing blood vessels. It is also used for measuring pressure and oxygen levels in different parts of the heart, checking pump functions, and diagnosing congenital heart defects. Furthermore, as it allows clinicians to administer fluid and other devices, the demand for medical tubing is increasing around the world.

Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/medical-tubing-market/requestsample

Medical Tubing Market Trends and Drivers:

At present, the rising demand for medical tubing as it is safe, reliable, and temperature resistant represents one of the primary factors influencing the market positively. Besides this, the increasing occurrence of various chronic disorders requiring detailed surgeries and treatment methods, along with the growing geriatric population across the globe, is offering a favorable market outlook.

In addition, the rising occurrence of respiratory diseases and cardiovascular complications caused by excessive smoking habits and breathing polluted air is propelling the growth of the market. Apart from this, increasing rates of hospitalization due to the rising occurrence of various novel viruses causing contagious diseases is contributing to the growth of the market. Additionally, there is a rise in the number of hospitals, clinics, and nursing homes worldwide providing quality healthcare services to patients.

This, coupled with the increasing advancement in improving diagnosis and treatment procedures for various life-threatening conditions, is supporting the growth of the market. Moreover, the rising utilization of medical tubing in the treatment of various forms of cancer, such as breast, prostate, cervical, lung, blood, and brain, is strengthening the growth of the market. Furthermore, the increasing usage of nano-medical tubes in advanced drug delivery systems, such as intracochlear and photo-thermally triggered drug delivery, is bolstering the growth of the market.

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/medical-tubing-market

Global Medical Tubing Market 2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Medical Tubing Companies:

ATAG spa, Avient Corporation, Bentec Medical, Hitachi Ltd., Microlumen Inc., NewAge Industries Inc., Nordson Corporation, Optinova, Spectrum Plastics Group, TE Connectivity Ltd., Trelleborg AB and Vanguard Products Corporation.

The report has segmented the market on the basis of region, product, structure, application and end user.

Breakup by Product: Silicone Polyolefins Polyvinyl Chloride Polycarbonates Fluoropolymers Others

Breakup by Structure: Single-Lumen Co-Extruded Multi-Lumen Tapered or Bump Tubing Braided Tubing

Breakup by Application: Bulk Disposable Tubing Drug Delivery Systems Catheters Biopharmaceutical Laboratory Equipment Others

Breakup by End User: Hospitals and Clinics Ambulatory Surgical Centers Medical Labs Others

Breakup by Region: North America: (United States, Canada) Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America: (Brazil, Mexico, Others) Middle East and Africa

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report: Market Performance (2016-2021) Market Outlook (2022- 2027) Porters Five Forces Analysis Market Drivers and Success Factors SWOT Analysis Value Chain Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Browse Other Related Reports:

Cholera Vaccines Market Report 2023-2028 : https://www.imarcgroup.com/cholera-vaccines-market

Blood Collection Market Report : https://www.imarcgroup.com/blood-collection-market

Intraoral Scanners Market Report 2023-2028: https://www.imarcgroup.com/intraoral-scanners-market

Gene Therapy Market Report : https://www.imarcgroup.com/gene-therapy-market

X-ray Machine Manufacturing Market Report 2023-2028 : https://www.imarcgroup.com/x-ray-machine-manufacturing-market

C-Arms Market Report : https://www.imarcgroup.com/c-arms-market

Hospital Stretchers Market Report :https://www.imarcgroup.com/hospital-stretchers-market

Biobanking Market Report 2023-2028 : https://www.imarcgroup.com/biobanking-market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact Us:

IMARC Services Private Limited. 134 N 4th St. Brooklyn, NY 11249, USA Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Anand RanjanIMARC Services Private Limited+1 6317911145email us here

View original post here:
Medical Tubing Market Research Report 2022 | Analysis, Trends, Business Growth and Forecast 2027 - EIN News